CoChat

Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma

Yang, Jen-Fu, Huang, Wen-Yen, Lo, Cheng-Hsiang, Lee, Meei-Shyuan, Lin, Chun-Shu, Shen, Po-Chien, Dai, Yang-Hong, Wang, Ying-Fu, Chen, Teng-Wei · 2022 · Scientific Reports
Cited by 5

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The relationship between sarcopenia and treatment outcomes, especially in patients with hepatocellular carcinoma (HCC) undergoing stereotactic body radiotherapy (SBRT) has not been well-explored. This study aimed to investigate the effects of sarcopenia on the survival and toxicity after SBRT in patients with HCC. We included 137 patients with HCC treated with SBRT between 2008 and 2018. Sarcopenia was defined as a skeletal muscle index (SMI) of < 49 cm 2/m 2 for men and < 31 cm 2/m 2 for women using computed tomography images at the mid-level of the third lumbar vertebra. The SMI change was presented as the change per 90 days. The Kaplan–Meier method was used for survival estimation, and the Cox regression was used to determine prognosticators. Sarcopenia was present in 67 of 137 eligible patients. With the median follow-up of 14.1 months and 32.7 months in the entire cohort and in those alive, respectively, patients with pre-SBRT sarcopenia or SMI loss ≥ 7% after SBRT had worse overall survival than their counterparts. Significant survival predictors on multivariate analysis were SMI loss ≥ 7% after SBRT [hazard ratio (HR): 1.96, p = 0.013], presence of extrahepatic metastasis (HR: 3.47, p < 0.001), neutrophil-to-lymphocyte ratio (HR: 1.79, p = 0.027), and multiple tumors (HR: 2.19, p = 0.003). Separate Cox models according to the absence and presence of pre-SBRT sarcopenia showed that SMI loss ≥ 7% remained a significant survival predictor in patients with sarcopenia (HR: 3.06, p = 0.017) compared with those without sarcopenia. SMI loss ≥ 7% is also a predictor of the Child–Pugh score increase by ≥ 2 points after SBRT. SMI loss ≥ 7% after SBRT is a significant prognostic factor for worse survival and is associated with liver toxicity compared with pre-SBRT sarcopenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-022-21443-6

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 40

  1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424. https://doi.org/10.3322/caac.21492 (2018). · DOI · Paper page
  2. Bujold, A. et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J. Clin. Oncol. 31(13), 1631–1639. https://doi.org/10.1200/jco.2012.44.1659 (2013). · DOI · Paper page
  3. Rim, C. H., Kim, H. J. & Seong, J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother. Oncol. 131, 135–144. https://doi.org/10.1016/j.radonc.2018.12.005 (2019). · DOI · Paper page
  4. Munoz-Schuffenegger, P. et al. Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion. Radiother. Oncol. 156, 120–126. https://doi.org/10.1016/j.radonc.2020.11.033 (2021). · DOI
  5. Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet 393(10191), 2636–2646. https://doi.org/10.1016/s0140-6736(19)31138-9 (2019). · DOI · Paper page
  6. Williams, G. R., Dunne, R. F., Giri, S., Shachar, S. S. & Caan, B. J. Sarcopenia in the older adult with cancer. J. Clin. Oncol. 39(19), 2068–2078. https://doi.org/10.1200/jco.21.00102 (2021). · DOI · Paper page
  7. Pamoukdjian, F. et al. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. Clin. Nutr. 37(4), 1101–1113. https://doi.org/10.1016/j.clnu.2017.07.010 (2018). · DOI · Paper page
  8. Shachar, S. S., Williams, G. R., Muss, H. B. & Nishijima, T. F. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur. J. Cancer. 57, 58–67. https://doi.org/10.1016/j.ejca.2015.12.030 (2016). · DOI · Paper page
  9. Collins, J., Noble, S., Chester, J., Coles, B. & Byrne, A. The assessment and impact of sarcopenia in lung cancer: A systematic literature review. BMJ Open 4(1), e003697. https://doi.org/10.1136/bmjopen-2013-003697 (2014). · DOI · Paper page
  10. Lee, J. et al. Skeletal muscle loss is an imaging biomarker of outcome after definitive chemoradiotherapy for locally advanced cervical cancer. Clin. Cancer Res. 24(20), 5028–5036. https://doi.org/10.1158/1078-0432.ccr-18-0788 (2018). · DOI
  11. Zhang, S. et al. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study. Clin. Nutr. 38(6), 2881–2888. https://doi.org/10.1016/j.clnu.2018.12.025 (2019). · DOI
  12. van Rijn-Dekker, M. I. et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother. Oncol. 147, 103–110. https://doi.org/10.1016/j.radonc.2020.03.014 (2020). · DOI
  13. Abe, S. et al. Preoperative sarcopenia is a poor prognostic factor in lower rectal cancer patients undergoing neoadjuvant chemoradiotherapy: A retrospective study. Int. J. Clin. Oncol. 27(1), 141–153. https://doi.org/10.1007/s10147-021-02062-z (2022). · DOI
  14. Ebadi, M. et al. Skeletal muscle pathological fat infiltration (myosteatosis) is associated with higher mortality in patients with cirrhosis. Cells https://doi.org/10.3390/cells11081345 (2022). · DOI
  15. Chang, K. V. et al. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: A systematic review and meta-analysis. Liver Cancer. 7(1), 90–103. https://doi.org/10.1159/000484950 (2018). · DOI
  16. Kim, N. et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol. Immunother. 70(6), 1593–1603. https://doi.org/10.1007/s00262-020-02794-3 (2021). · DOI
  17. Iritani, S. et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J. Gastroenterol. 50(3), 323–332. https://doi.org/10.1007/s00535-014-0964-9 (2015). · DOI · Paper page
  18. Voron, T. et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann. Surg. 261(6), 1173–1183. https://doi.org/10.1097/SLA.0000000000000743 (2015). · DOI · Paper page
  19. Harimoto, N. et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br. J. Surg. 100(11), 1523–1530. https://doi.org/10.1002/bjs.9258 (2013). · DOI · Paper page
  20. Loosen, S. H. et al. Sarcopenia is a negative prognostic factor in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies. Cancers https://doi.org/10.3390/cancers11101503 (2019). · DOI
  21. Nishikawa, H. et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol. Lett. 14(2), 1637–1647. https://doi.org/10.3892/ol.2017.6287 (2017). · DOI
  22. Fujita, M. et al. Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: A multicenter study in Tohoku, Japan. Sci. Rep. 12(1), 6479. https://doi.org/10.1038/s41598-022-10514-3 (2022). · doi:10.1038/s41598-022-10514-3
  23. Huang, W. Y. et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 84(2), 355–361. https://doi.org/10.1016/j.ijrobp.2011.11.058 (2012). · doi:10.1016/j.ijrobp.2011.11.058
  24. Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30(1), 52–60. https://doi.org/10.1055/s-0030-1247132 (2010). · DOI · Paper page
  25. Shen, W. et al. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J. Appl. Physiol. 97(6), 2333–2338. https://doi.org/10.1152/japplphysiol.00744.2004 (2004). · DOI · Paper page
  26. Mourtzakis, M. et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33(5), 997–1006. https://doi.org/10.1139/h08-075 (2008). · DOI · Paper page
  27. Yu, J. I. et al. Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. Radiother. Oncol. 152, 19–25. https://doi.org/10.1016/j.radonc.2020.07.043 (2020). · DOI
  28. Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9(7), 629–635. https://doi.org/10.1016/s1470-2045(08)70153-0 (2008). · DOI · Paper page
  29. Martin, L. et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31(12), 1539–1547. https://doi.org/10.1200/jco.2012.45.2722 (2013). · DOI · Paper page
  30. Sakurai, K. et al. Adverse effects of low preoperative skeletal muscle mass in patients undergoing gastrectomy for gastric cancer. Ann. Surg. Oncol. 24(9), 2712–2719. https://doi.org/10.1245/s10434-017-5875-6 (2017). · DOI
  31. Perisetti, A. et al. Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions. World J. Gastroenterol. 28(4), 432–448. https://doi.org/10.3748/wjg.v28.i4.432 (2022). · DOI
  32. Xu, L. et al. Preoperative computed tomography-assessed skeletal muscle index is a novel prognostic factor in patients with hepatocellular carcinoma following hepatectomy: A meta-analysis. J. Gastrointest. Oncol. 11(5), 1040–1053. https://doi.org/10.21037/jgo-20-122 (2020). · DOI
  33. Shiba, S. et al. No deterioration in clinical outcomes of carbon ion radiotherapy for sarcopenia patients with hepatocellular carcinoma. Anticancer Res. 38(6), 3579–3586. https://doi.org/10.21873/anticanres.12631 (2018). · doi:10.21873/anticanres.12631
  34. Lee, J., Cho, Y., Park, S., Kim, J. W. & Lee, I. J. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with radiotherapy. Front. Oncol. 9, 1075. https://doi.org/10.3389/fonc.2019.01075 (2019). · DOI
  35. Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl. Cancer Inst. 106(6), dju124. https://doi.org/10.1093/jnci/dju124 (2014). · DOI · Paper page
  36. Haram, A. et al. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review. J. Surg. Oncol. 115(4), 470–479. https://doi.org/10.1002/jso.24523 (2017). · DOI · Paper page
  37. Feliciano, E. M. C. et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: Results from the C SCANS study. JAMA Oncol. 3(12), e172319. https://doi.org/10.1001/jamaoncol.2017.2319 (2017). · DOI · Paper page
  38. Cho, Y. et al. Prognostic significance of sarcopenia with inflammation in patients with head and neck cancer who underwent definitive chemoradiotherapy. Front. Oncol. 8, 457. https://doi.org/10.3389/fonc.2018.00457 (2018). · DOI
  39. Velec, M. et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 97(5), 939–946. https://doi.org/10.1016/j.ijrobp.2017.01.221 (2017). · DOI
  40. Chen, L. K. et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J. Am. Med. Dir. Assoc. 21(3), 300–307.e2. https://doi.org/10.1016/j.jamda.2019.12.012 (2020). · DOI · Paper page

Metadata

Authors
Yang, J.-F., Huang, W.-Y., Lo, C.-H., Lee, M.-S., Lin, C.-S., Shen, P.-C., Dai, Y.-H., Wang, Y.-F., & Chen, T.-W.
Venue
Scientific Reports
Published
2022-11-09
Volume
12
Issue
1
ISSN
2045-2322
Cited by
5
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41598-022-21443-6
The paper
Yang, J.-F., Huang, W.-Y., Lo, C.-H., Lee, M.-S., Lin, C.-S., Shen, P.-C., Dai, Y.-H., Wang, Y.-F., & Chen, T.-W. (2022). Significant muscle loss after stereotactic body radiotherapy predicts worse survival in patients with hepatocellular carcinoma. Scientific Reports. https://doi.org/10.1038/s41598-022-21443-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.